See more : Bajaj Auto Limited (BAJAJ-AUTO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Vivani Medical, Inc. (VANI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivani Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Coastal Caribbean Oils & Minerals, Ltd. (COCBF) Income Statement Analysis – Financial Results
- Superbag Company, Limited (3945.T) Income Statement Analysis – Financial Results
- Zoomability Int AB (ZOOM.ST) Income Statement Analysis – Financial Results
- BLUE INNOVATION CO LTD (5597.T) Income Statement Analysis – Financial Results
- Palinda Group Holdings Limited (8179.HK) Income Statement Analysis – Financial Results
Vivani Medical, Inc. (VANI)
About Vivani Medical, Inc.
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.38M | 6.90M | 7.96M | 3.99M | 8.95M | 3.40M | 1.56M | 1.37M |
| Cost of Revenue | 357.00K | 381.00K | 345.00K | 167.00K | 2.15M | 4.89M | 7.75M | 9.35M | 4.30M | 3.56M | 5.63M | 4.40M |
| Gross Profit | -357.00K | -381.00K | -345.00K | -167.00K | 1.23M | 2.01M | 211.00K | -5.36M | 4.65M | -160.28K | -4.06M | -3.03M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 36.31% | 29.12% | 2.65% | -134.60% | 51.93% | -4.72% | -259.72% | -221.58% |
| Research & Development | 16.97M | 14.17M | 11.00M | 6.87M | 16.50M | 10.21M | 7.99M | 5.35M | 3.04M | 5.04M | 3.25M | 3.05M |
| General & Administrative | 10.00M | 7.07M | 2.32M | 2.38M | 9.23M | 10.69M | 10.93M | 10.08M | 8.22M | 6.57M | 4.17M | 4.03M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 6.10M | 11.34M | 9.57M | 8.99M | 8.94M | 6.84M | 3.30M | 2.19M |
| SG&A | 10.00M | 7.07M | 2.32M | 2.38M | 15.33M | 26.63M | 23.56M | 21.77M | 20.67M | 13.41M | 7.47M | 6.22M |
| Other Expenses | 0.00 | 475.00K | -91.00K | -36.00K | 3.35M | 4.60M | 2.64M | -727.00K | -991.00K | 2.62M | 3.22M | 3.73M |
| Operating Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 31.82M | 36.83M | 28.92M | 27.85M | 24.70M | 21.07M | 13.93M | 12.99M |
| Cost & Expenses | 26.97M | 21.24M | 13.32M | 9.24M | 33.98M | 41.72M | 36.67M | 37.20M | 29.00M | 24.63M | 19.56M | 17.39M |
| Interest Income | 0.00 | 0.00 | 0.00 | 16.00K | 362.00K | 86.00K | 93.00K | 31.00K | 2.00K | 9.11K | 7.45K | 7.51K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 7.03M | 5.01M | 267.03K |
| Depreciation & Amortization | 357.00K | 381.00K | 345.00K | 167.00K | 414.00K | 435.00K | 457.00K | 432.00K | 335.00K | 279.18K | 315.77K | 324.71K |
| EBITDA | -26.61M | -19.16M | -12.98M | -8.89M | -33.18M | -34.66M | -28.06M | -32.75M | -19.68M | -27.89M | -17.64M | -15.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -893.25% | -498.69% | -354.75% | -822.53% | -220.25% | -820.75% | -1,127.18% | -1,147.39% |
| Operating Income | -26.97M | -21.24M | -13.32M | -9.24M | -30.60M | -34.83M | -28.71M | -33.21M | -20.05M | -21.23M | -18.00M | -16.02M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -905.50% | -505.00% | -360.48% | -833.38% | -223.99% | -624.91% | -1,150.05% | -1,171.82% |
| Total Other Income/Expenses | 1.31M | 7.35M | 550.00K | -36.00K | -3.00M | -269.00K | 193.00K | 31.00K | 29.00K | -13.97M | -4.97M | -257.74K |
| Income Before Tax | -25.65M | -13.89M | -12.77M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| Income Tax Expense | 0.00 | -7.35M | -641.00K | 147.70K | 362.00K | 86.00K | 93.00K | 31.00K | 58.00K | -6.93M | 42.22K | 9.29K |
| Net Income | -25.65M | -6.54M | -12.13M | -9.28M | -33.59M | -35.09M | -28.52M | -33.18M | -20.02M | -35.20M | -22.97M | -16.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -994.14% | -508.90% | -358.06% | -832.60% | -223.66% | -1,035.99% | -1,467.73% | -1,190.67% |
| EPS | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| EPS Diluted | -0.50 | -0.17 | -1.10 | -1.35 | -6.85 | -12.69 | -12.64 | -20.13 | -13.48 | -10.31 | -4.87 | -3.45 |
| Weighted Avg Shares Out | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
| Weighted Avg Shares Out (Dil) | 50.85M | 38.24M | 11.03M | 6.86M | 4.90M | 2.77M | 2.26M | 1.65M | 1.48M | 3.41M | 4.72M | 4.72M |
Second Sight Medical stock tumbles after private placement of stock at 46% discount
Shares of Second Sight Medical Products Inc. tumbled 25% to pace all premarket decliners on Wednesday, after the implantable visual prosthetics company announced a large private placement of common stock. The share sale comes after the stock skyrocketed more than...
EYES Stock Price Falls Over 20% Pre-Market: Why It Happened
The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) fell by over 20% pre-market. This is why it happened.
Second Sight Medical Products Announces $27.9 Million Private Placement of Common Stock
LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES), (the "Company" or "Second Sight"), a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that...
Second Sight Medical Products Is No Short Squeeze
EYES stock jumped higher off a very encouraging FDA approval but now is the time to apply a little more scrutiny to the Second Sight Medical investment. The post Second Sight Medical Products Is No Short Squeeze appeared first on...
FDA Approval Sheds New Light on Second Sight Medical Products
You won't believe your eyes when you see the ultra-bullish price action in EYES stock, along with the game-changing regulatory announcement. The post FDA Approval Sheds New Light on Second Sight Medical Products appeared first on InvestorPlace.
EYES Stock Price Increased 486.07% Over The Past Month: Why It Happened
The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by 486.07% over the past month. This is why it happened.
EYES Stock Price Increases 35.71%: Why It Happened
The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) increased by 35.71% yesterday. This is why it happened.
EYES Stock Price Increases Over 30% Pre-Market: Why It Happened
The stock price of Second Sight Medical Products Inc (NASDAQ: EYES) is trading at over 30% pre-market. This is why it happened.
Continuation of the business combination project between Pixium Vision et Second Sight Medical Products
Paris, France, March 09, 2021 – Pixium Vision (Euronext Growth Paris - FR0011950641) announces that the business combination with Second Sight Medical Products, Inc. (« Second Sight ») (Nasdaq: EYES) continues under the terms announced to the market on January 6, 2021.
Why Second Sight Medical Products Has Skyrocketed 723% In 2 Trading Sessions
Second Sight Medical Products Inc (NASDAQ: EYES) shares have soared above 723% over the previous two trading sessions with the stock touching an intraday high of $14.83 on Monday. The shares registered a spike of nearly 103% as of Monday's closing.
Source: https://incomestatements.info
Category: Stock Reports